Geneva, Feb. 2 -- International Clinical Trials Registry received information related to the study (ChiCTR2600117101) titled 'Beromuzumab Plus Anlotinib Combined with SBRT for Patients with Hepatocellular Carcinoma Failing First-Line Targeted Therapy:A Single-Arm, Multicenter Clinical Study' on Jan. 20.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Southern Medical University Southern Hospital
Condition:
First-line targeted therapy failure in oligometastatic hepatocellular carcinoma
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-02-01
Target Sample Size: Experimental Group:29;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.ht...